Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab in Early Alzheimer's Disease
NCT01767311Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2012
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of lecanemab in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Dec 2012; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01767311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767311.